203 related articles for article (PubMed ID: 22404985)
1. The anti-CD74 humanized monoclonal antibody, milatuzumab, which targets the invariant chain of MHC II complexes, alters B-cell proliferation, migration, and adhesion molecule expression.
Frölich D; Blassfeld D; Reiter K; Giesecke C; Daridon C; Mei HE; Burmester GR; Goldenberg DM; Salama A; Dörner T
Arthritis Res Ther; 2012 Mar; 14(2):R54. PubMed ID: 22404985
[TBL] [Abstract][Full Text] [Related]
2. Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus.
Daridon C; Blassfeld D; Reiter K; Mei HE; Giesecke C; Goldenberg DM; Hansen A; Hostmann A; Frölich D; Dörner T
Arthritis Res Ther; 2010; 12(6):R204. PubMed ID: 21050432
[TBL] [Abstract][Full Text] [Related]
3. Milatuzumab-SN-38 conjugates for the treatment of CD74+ cancers.
Govindan SV; Cardillo TM; Sharkey RM; Tat F; Gold DV; Goldenberg DM
Mol Cancer Ther; 2013 Jun; 12(6):968-78. PubMed ID: 23427296
[TBL] [Abstract][Full Text] [Related]
4. Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma.
Alinari L; Yu B; Christian BA; Yan F; Shin J; Lapalombella R; Hertlein E; Lustberg ME; Quinion C; Zhang X; Lozanski G; Muthusamy N; Prætorius-Ibba M; O'Connor OA; Goldenberg DM; Byrd JC; Blum KA; Baiocchi RA
Blood; 2011 Apr; 117(17):4530-41. PubMed ID: 21228331
[TBL] [Abstract][Full Text] [Related]
5. Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignancies.
Mao Y; Triantafillou G; Hertlein E; Towns W; Stefanovski M; Mo X; Jarjoura D; Phelps M; Marcucci G; Lee LJ; Goldenberg DM; Lee RJ; Byrd JC; Muthusamy N
Clin Cancer Res; 2013 Jan; 19(2):347-56. PubMed ID: 23209030
[TBL] [Abstract][Full Text] [Related]
6. HLA-DRα1 constructs block CD74 expression and MIF effects in experimental autoimmune encephalomyelitis.
Meza-Romero R; Benedek G; Yu X; Mooney JL; Dahan R; Duvshani N; Bucala R; Offner H; Reiter Y; Burrows GG; Vandenbark AA
J Immunol; 2014 May; 192(9):4164-73. PubMed ID: 24683185
[TBL] [Abstract][Full Text] [Related]
7. Prevention of acute graft-versus-host disease in a xenogeneic SCID mouse model by the humanized anti-CD74 antagonistic antibody milatuzumab.
Chen X; Chang CH; Stein R; Cardillo TM; Gold DV; Goldenberg DM
Biol Blood Marrow Transplant; 2013 Jan; 19(1):28-39. PubMed ID: 23025988
[TBL] [Abstract][Full Text] [Related]
8. Proinflammatory Signature of the Dysfunctional Endothelium in Pulmonary Hypertension. Role of the Macrophage Migration Inhibitory Factor/CD74 Complex.
Le Hiress M; Tu L; Ricard N; Phan C; Thuillet R; Fadel E; Dorfmüller P; Montani D; de Man F; Humbert M; Huertas A; Guignabert C
Am J Respir Crit Care Med; 2015 Oct; 192(8):983-97. PubMed ID: 26203495
[TBL] [Abstract][Full Text] [Related]
9. Macrophage migration inhibitory factor and CD74 regulate macrophage chemotactic responses via MAPK and Rho GTPase.
Fan H; Hall P; Santos LL; Gregory JL; Fingerle-Rowson G; Bucala R; Morand EF; Hickey MJ
J Immunol; 2011 Apr; 186(8):4915-24. PubMed ID: 21411731
[TBL] [Abstract][Full Text] [Related]
10. CD74 interferes with the expression of fas receptor on the surface of lymphoma cells.
Berkova Z; Wang S; Ao X; Wise JF; Braun FK; Rezaeian AH; Sehgal L; Goldenberg DM; Samaniego F
J Exp Clin Cancer Res; 2014 Oct; 33(1):80. PubMed ID: 25304249
[TBL] [Abstract][Full Text] [Related]
11. LPS-mediated cell surface expression of CD74 promotes the proliferation of B cells in response to MIF.
Klasen C; Ziehm T; Huber M; Asare Y; Kapurniotu A; Shachar I; Bernhagen J; El Bounkari O
Cell Signal; 2018 Jun; 46():32-42. PubMed ID: 29476963
[TBL] [Abstract][Full Text] [Related]
12. Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma.
Kaufman JL; Niesvizky R; Stadtmauer EA; Chanan-Khan A; Siegel D; Horne H; Wegener WA; Goldenberg DM
Br J Haematol; 2013 Nov; 163(4):478-86. PubMed ID: 24112026
[TBL] [Abstract][Full Text] [Related]
13. Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines.
Stein R; Smith MR; Chen S; Zalath M; Goldenberg DM
Clin Cancer Res; 2009 Apr; 15(8):2808-17. PubMed ID: 19351768
[TBL] [Abstract][Full Text] [Related]
14. Milatuzumab: a promising new agent for the treatment of lymphoid malignancies.
Mark T; Martin P; Leonard JP; Niesvizky R
Expert Opin Investig Drugs; 2009 Jan; 18(1):99-104. PubMed ID: 19053886
[TBL] [Abstract][Full Text] [Related]
15. Surface expression of CD74 by type II alveolar epithelial cells: a potential mechanism for macrophage migration inhibitory factor-induced epithelial repair.
Marsh LM; Cakarova L; Kwapiszewska G; von Wulffen W; Herold S; Seeger W; Lohmeyer J
Am J Physiol Lung Cell Mol Physiol; 2009 Mar; 296(3):L442-52. PubMed ID: 19136583
[TBL] [Abstract][Full Text] [Related]
16. FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death.
Alinari L; Mahoney E; Patton J; Zhang X; Huynh L; Earl CT; Mani R; Mao Y; Yu B; Quinion C; Towns WH; Chen CS; Goldenberg DM; Blum KA; Byrd JC; Muthusamy N; Praetorius-Ibba M; Baiocchi RA
Blood; 2011 Dec; 118(26):6893-903. PubMed ID: 22042694
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomas.
Martin P; Furman RR; Rutherford S; Ruan J; Ely S; Greenberg J; Coleman M; Goldsmith SJ; Leonard JP
Leuk Lymphoma; 2015; 56(11):3065-70. PubMed ID: 25754579
[TBL] [Abstract][Full Text] [Related]
18. A functional heteromeric MIF receptor formed by CD74 and CXCR4.
Schwartz V; Lue H; Kraemer S; Korbiel J; Krohn R; Ohl K; Bucala R; Weber C; Bernhagen J
FEBS Lett; 2009 Sep; 583(17):2749-57. PubMed ID: 19665027
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of CD74 and its potential association with disease severity in subjects with ischemic stroke.
Yang L; Kong Y; Ren H; Li M; Wei CJ; Shi E; Jin WN; Hao J; Vandenbark AA; Offner H
Neurochem Int; 2017 Jul; 107():148-155. PubMed ID: 27884769
[TBL] [Abstract][Full Text] [Related]
20. The secret second life of an innocent chaperone: the story of CD74 and B cell/chronic lymphocytic leukemia cell survival.
Shachar I; Haran M
Leuk Lymphoma; 2011 Aug; 52(8):1446-54. PubMed ID: 21417823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
